OpenBit ResearchOpenBit
中文

What's driving Ascendis Pharma A/S (ASND)

Compiled from the engine's research, source claims and public filings in this dossier. Each has its own data date, listed below.

Research summary

Ascendis Regains TransCon Metabolic and Cardiovascular Rights

Why it matters now

Ascendis is the issuer receiving the reverted rights, which changes its strategic control and potential commercialization scope in metabolic and cardiovascular disease.

Next checkpoint

ASND earnings (expected 2026-11-11)

This checkpoint sits on a shared driver. The engine does not explain how it carries over to ASND, so treat it as context, not a verified checkpoint for this company.

What would break the thesis

A subsequent authoritative disclosure establishes that the rights did not revert to Ascendis or that the termination was reversed.

Research drivers

  • Ascendis Regains TransCon Metabolic and Cardiovascular Rights

    Bullish · Cooling · Updated

    Rights to TransCon products in metabolic and cardiovascular disease have reverted to Ascendis after the collaboration ended.

  • Ascendis Licensed-Product Economics

    Bearish · Emerging · Updated

    Ascendis has licenses for the named products and will pay BioMarin royalties on sales, creating a material contractual deduction from product economics through May 2030.

Source claims

Source labels are as recorded in our data. The dossier does not include links to the originals, so these are not verified quotations.

  • BioMarin Pharmaceutical entered into a license deal with Ascendis Pharma under which BioMarin granted Ascendis licenses for TransCon CNP, navepegritide, and Yuviwel.

    Relayed by: Benzinga · Event date on record:

  • Ascendis Pharma said its collaboration with Novo Nordisk has been terminated and that all rights to TransCon products in metabolic and cardiovascular disease will revert to Ascendis.

    Relayed by: Benzinga · Event date on record:

  • Ascendis Pharma will pay BioMarin royalties on sales at rates of 20% in the U.S. and 18% in the EU, Brazil, and Slovakia until May 2030.

    Relayed by: Benzinga · Ingestion date (event date unconfirmed):

Related sectors

Biotech

Filed holders

This dossier has no filed holders to show. That does not mean no institution holds it.